218 related articles for article (PubMed ID: 28444816)
1. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.
Gantner P; Cuzin L; Allavena C; Cabie A; Pugliese P; Valantin MA; Bani-Sadr F; Joly V; Ferry T; Poizot-Martin I; Garraffo R; Peytavin G; Fafi-Kremer S; Rey D;
HIV Med; 2017 Oct; 18(9):704-708. PubMed ID: 28444816
[No Abstract] [Full Text] [Related]
2. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM; Hung CC; Brinson C; Castelli F; Girard PM; Kahl LP; Blair EA; Angelis K; Wynne B; Vandermeulen K; Underwood M; Smith K; Gartland M; Aboud M
Lancet; 2018 Mar; 391(10123):839-849. PubMed ID: 29310899
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
Hester EK; Astle K
Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
[No Abstract] [Full Text] [Related]
4. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
Capetti AF; Astuti N; Cattaneo D; Rizzardini G
Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1183-1192. PubMed ID: 28854832
[TBL] [Abstract][Full Text] [Related]
5. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.
Corado KC; Caplan MR; Daar ES
Drug Des Devel Ther; 2018; 12():3731-3740. PubMed ID: 30464404
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
Capetti AF; Cossu MV; Paladini L; Rizzardini G
Expert Opin Pharmacother; 2018 Jan; 19(1):65-77. PubMed ID: 29246084
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults.
Properzi M; Magro P; Castelli F; Quiros-Roldan E
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):877-887. PubMed ID: 30392419
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Boswell R; Foisy MM; Hughes CA
Ann Pharmacother; 2018 Jul; 52(7):681-689. PubMed ID: 29442543
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
10. Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
Casado JL; Monsalvo M; Rojo AM; Fontecha M; Rodriguez-Sagrado MA
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):561-570. PubMed ID: 29775399
[TBL] [Abstract][Full Text] [Related]
11. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Cento V; Perno CF
J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Mehta R; Wolstenholme A; Di Lullo K; Fu C; Joshi S; Crauwels H; Givens N; Vanveggel S; Wynne B; Adkison K
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987139
[TBL] [Abstract][Full Text] [Related]
13. Juluca - a two-drug complete regimen for HIV.
Med Lett Drugs Ther; 2018 Dec; 60(1561):e202-e204. PubMed ID: 30653480
[No Abstract] [Full Text] [Related]
14. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
Ribera E
AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir-rilpivirine coformulation.
Sun HY; Chang SY; Hung CC
Curr Opin HIV AIDS; 2018 Jul; 13(4):320-325. PubMed ID: 29553948
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
Med Lett Drugs Ther; 2019 Aug; 61(1579):134-136. PubMed ID: 31581158
[No Abstract] [Full Text] [Related]
17. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
[TBL] [Abstract][Full Text] [Related]
18. Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population.
Brizzi MB; Chiampas TD; Michienzi SM; Young JD; Patel MC; Badowski ME
Int J STD AIDS; 2019 Oct; 30(12):1163-1168. PubMed ID: 31558124
[No Abstract] [Full Text] [Related]
19. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
Merli M; Galli L; Marinaro L; Ariaudo A; Messina E; Uberti-Foppa C; Castagna A; D'Avolio A; Lazzarin A; Bonora S; Hasson H
J Antimicrob Chemother; 2017 Mar; 72(3):812-815. PubMed ID: 27999010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
